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INTRODUCTION 
The concept that passenger leukocytes are more 
"immunogenic" and thus initiate rejection, which is 
ultimately directed against the parenchyma and vessels of 
solid organ allografts, was first proposed by Snell (1) and 
later proved by Steinmuller (2). Steinman and Cohn (3-6) 
subsequently showed that a distinct type of passenger 
leukocyte, the dendritic cell, provides the most potent of 
the allogeneic stimuli. Besides dendritic cells, which 
reside in the interstitium of all allografts, every organ 
also carries with it a variable number of T and B 
lymphocytes, macrophages and myeloid cells. Therefore, each 
type of allograft presents a heterogenous stimulatory 
profile as well as the potential for graft-versus-host (GVH) 
reactions. 
Based on the seemingly logical assumption that the 
highly immunogenic passenger leukocytes are deleterious to 
graft survival, attempts have been made to deplete donor 
hematolymphoid cells from organs prior to transplantation 
(7-10). While this approach can clearly yield improved 
short-term results, leukocyte-depleted allografts are still 
eventually rejected. Even epidermal allografts, which 
consist of pure keratinocyte cultures are rejected (11) 
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In a seeming paradox, donor hematolymphoid cells, 
particularly those from the bone marrow, are known to carry 
with them the ability to render the recipient's immune 
system specifically unresponsive to subsequent organ 
allografts (12-19). Owen (20) was the first to show that 
cattle fetuses whose individual placentas had placental 
cross-circulation (freemartins) subsequently developed 
"chimeric" hematolymphoid systems. The chimerism, which was 
a mixture of the ABO (and presumably other) phenotypes of 
the fetuses persisted, for a lifetime and was associated 
with subsequent cross-tolerance to tissue and whole organ 
(kidney) grafts (21). 
The lead provided by Owen caused Burnet and Fenner (22) 
to predict the feasibility of iatrogenetically producing 
acquired tolerance by exposing fetuses to immunologically 
active adult tissues in utero, and this feat was 
accomplished in 1953 with spleen cells in mice by 
Billingham, Brent, and Medawar (12,23) in what was a 
decisive stimulus toward the ultimate development of 
clinical transplantation. Ensuing experimental models of 
radiation and monoclonal antibody-induced mixed 
hematolymphoid chimeras in adults are based on this 
principle. In general, these models attempt to recapitulate 
development of the neonatal immune system in a "twin-like" 
environment. First, the recipient's immune system is 
disabled with drugs or radiation, which is followed by an 
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infusion of donor hematolymphoid cells. In this paradigm, 
uncommitted stem cells which have seeded the bone marrow, 
produce progeny that are educated in the recipient's thymus 
and immune system. Eventually, tolerance to a subsequent 
solid organ allograft is produced, but how this occurs is 
poorly understood. 
Although Owen's original observations in freemartin 
cattle were of mixed chimerism, as opposed to the full 
chimerism of the Billingham-Brent-Medawar model, this 
crucial difference was seldom emphasized. The association 
of acquired tolerance with full chimerism, meaning complete 
replacement of the host hematolymphopoietic system with that 
of the donor, was so strong following the Billingham-Brent-
Medawar reports that stable and permanent mixed chimerism as 
a means of tolerance induction was rarely mentioned again 
for almost 4 decades. In fact, hematolymphopoietic 
replacement was the dogma by which bone marrow 
transplantation per se was developed experimentally and 
ultimately used clinically (24,25). This approach was long 
envisioned to be the potential means by which tolerance 
could be induced for whole organ grafts (13). 
Using the total bone marrow conditioning approach, 
permanent tolerance to a variety of organs has been produced 
across partial and full MHC, and even across species 
barriers (13-19). However, there were two major drawbacks 
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which prevented clinical application. One was that the 
conditioning regimens necessary to ensure donor bone marrow 
engraftment were extreme, with an inherent short- and long-
term morbidity. The second and more fundamental problem 
first described by Billingham and Brent (26) in mice was the 
development of graft versus host disease (GVHD). The risk 
from this complication in which the new immunologic 
apparatus destroyed the host was directly related to the 
degree of histoincompatibility between donor and recipient 
(27), restricting the marrow or other similar conditioning 
strategies to patients with perfect MHC-matched donors 
(24,25,28,29) . 
The entrenchment and durability of this therapeutic 
doctrine as a rational approach to tolerance induction for 
whole organs is really quite remarkable in view of the 
obvious fact that it was not fundamentally feasible. In the 
meanwhile, an important but long unexploited experimental 
observation by Liegeois et al (30,31) suggested as early as 
1974 that complete extirpation and replacement of the 
recipient hematolymphopoetic system was not an absolute 
requirement for engraftment of donor bone marrow and the 
consequent induction of tolerance for other donor tissues 
and organs. These investigations were performed in Paris in 
an attempt to explain donor specific nonreactivity to skin 
grafts induced first by Monaco, Wood, and Russell (32) and 
then by Wood, Monaco, Gozzo, and Liegeois (33) with 
,,-------------------------,,----------
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antilymphocyte serum (ALS) plus delayed intravenous bone 
marrow infusion one week later. Using karyotyping 
techniques, Liegeois et al (30,31) demonstrated 
progressively declining (always small) numbers of 
replicating donor bone marrow cells in the recipient's 
spleens as long as 134 days after the bone marrow-skin 
transplantations, a condition which they termed 
microchimerism. Although Liegeois et al (30,31) and Monaco 
(34) were intrigued by this finding, their assumption and 
that of others was that the decline in identifiable donor 
cells was premonitory to their extinction. This point of 
view that these chimeric cells were transient, prevented the 
recognition of the full significance of Liegeois's findings. 
In addition, these findings following bone marrow infusion 
were not suspected to pertain also to passenger leukocytes 
from whole organs. 
In principle, Slavin and Strober et al (14-16) showed 
the same thing as Liegeois in 1977, but with the additional 
information that the mixed microchimerism could be 
persistent and stable for long periods. In rats treated 
with total lymphoid (not total body) irradiation (TLI) and 
donor bone marrow infusion, they produced mixed chimerism, 
emphasized the lack of GVHD in their animals, and showed 
that the donor and recipient were reciprocally tolerant ---
analogous to Owens' freemartin cattle (20). Subsequently, 
Ildstad and Sachs (17) provided convincing confirmation by 
331 
cytoablating recipients and reconstituting them with mixed 
donor and recipient marrow, with consequent mixed allogeneic 
or xenogeneic chimerism. Slavin and Strober's experiments 
led to clinical trials of kidney and liver transplantation 
with donor bone marrow augmentation more than a decade ago 
(35-42), but these were abandoned because of the conviction 
that the bone marrow was an unnecessary adjuvant to the TLI, 
and was potentially harmful (38-42). 
Nearly a decade after the reports by Billingham, Brent, 
and Medawar (12,23), a seemingly different therapeutic dogma 
was developed with continuous chemical immunosuppression 
that allowed increasingly successful whole organ 
transplantation with graft acceptance by what were widely 
construed as different immunologic mechanisms (44-51). This 
misconception was dispelled in 1992 with the demonstration 
that long-surviving human kidney, liver, and other whole 
organ recipients had low level mixed allogeneic chimerism 
(52-57) from dissemination and survival of passenger 
leukocytes leaving the graft. The pattern and time course 
of the cell migration and the movement into the graft of 
recipient cells of the same lineages could be easily 
identified after liver transplantation in experimental 
animals (58,59). This was a mechanism that defied the logic 
of the diametrically opposite strategy of trying to deplete 
the passenger leukocytes described in the introduction of 
this article. 
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Definition of a Paradox 
Although donor hematolymphoid cells have been 
identified both as the most immunogenic (1-11) and the most 
tolerogenic cells (12-19) associated with solid organ 
allografts, there have been few attempts until recently to 
reconcile these apparently paradoxical roles. One reason 
apparently has been the assumption that the passenger 
leukocytes transferred with a solid organ were fundamentally 
different from those found in the bone marrow. In addition, 
many investigators have also assumed that the number of 
transferred donor hematolymphoid cells was insignificant and 
the cells were rapidly destroyed. The recent studies in 
humans and experimental animals have shown that both of 
these assumptions were invalid (52-59). In fact, we have 
proposed that persistence of rare passenger leukocytes in 
recipient tissues is conducive to, and the explanation of, 
graft acceptance. Properly addressing this opposite effect 
paradox may yield a different perspective of transplantation 
biology. 
The following is not intended as a review of the area 
of passenger leukocytes in transplantation biology. Rather 
this manuscript should be considered as a hypothesis to 
explain how donor hematolymphoid cells transferred with the 
graft could assist in graft acceptance. A brief description 
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of the their role in provoking rejection and tolerization is 
also presented. This aspect is particularly important to 
development of the hypothesis. 
Passenger Leukocytes Under Temporary Immunosuppression 
or in Untreated Organ Allograft Recipients 
The Liver --- The early events leading to the chimeric 
state after liver transplantation have been studied in rats 
(58) and mice (59), including the pathways of passenger 
leukocyte dissemination. Within minutes or hours, some of 
these cells leave the liver and home to the spleen, lymph 
nodes, thymus, and bone marrow where they are destroyed by 
rejection in most animals models except those using mice as 
subjects. However, under temporary immunosuppression in 
rats (2 weeks daily FK 506), these mononuclear cells pause 
for about 2 weeks in the lymphoid organs, but then break out 
and move secondarily to all recipient tissues (58). Rat 
liver recipients treated in this way (for example, Lewis 
[LEW] to Brown Norway [BN]) survive indefinitely without 
further treatment and retain their graft and systemic 
chimerism. 
Interestingly, permanent survival of the engrafted 
livers occurs without any immunosuppression in some rat 
strain combinations of which BN to LEW has been most 
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completely studied (60), and it occurs without treatment in 
virtually all mouse strain combinations no matter how severe 
the histoincompatibility (59). The heavy endowment of the 
liver with potentially migratory white cells is thought to 
be the basis for the previously inexplicable phenomenon of 
"hepatic tolerogenicity". 
In fact, we believe that the foregoing migration and 
repopulation is the central mechanism of acceptance of all 
whole organ grafts (52-59). Although this is a generic 
process, there are quantitative differences between organs 
in the density of the potentially migratory dendritic cells, 
macrophages, and lymphoid collections. The heavy endowment 
of the liver with the foregoing leukocyte lineages 
(including Kupffer cells) is a particularly striking feature 
that invites further speculation about the role of these 
cells in the well known tolerogenicity of this organ. 
The immunologic advantage of the liver relative to 
other organs includes a greater ease of inducing the 
acceptance of hepatic allografts (described above) or 
xenografts after a limited course of immunosuppression 
(47,49,61,62) or in swine (63-65) and some rat strain 
combinations (60,66) with no treatment at all. In addition, 
the transplanted liver graft is relatively resistant to the 
preformed antigraft antibodies that cause hyperacute 
rejection of the kidney and heart (67-70). Another quality 
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is its unusual ability to induce a state of unresponsiveness 
to other tissues and organs transplanted concomitantly or 
subsequently from the donor or donor strain (66,68,71) and 
even shield these organs from the hyperacute rejection 
caused by preformed allospecific (70) or xenospecific (72) 
antidonor antibodies. In all of these circumstances, the 
liver appears to quickly transform the recipient environment 
to one more favorable for all donor tissues including 
itself. All of these qualities of the liver are evident in 
practically every mouse strain combination, no matter what 
the degree of histoincompatibility (59). 
Other Organs --- The foregoing observations have been 
attributed to "hepatic tolerogenicity", incorrectly we 
believe, because the term implies that the hepatocytes are 
responsible. We have proposed that the crucial variable 
distinguishing the tolerogenicity of one organ graft from 
another under effective immunosuppression (or in some animal 
models without treatment) is its leukocyte, not its 
parenchymal component (56-59). This is a reversal of the 
immunogenic role described classically for the "passenger" 
white cells (1-10,73-76). Thus, because of its dense 
constituency of these migratory leukocytes, the liver is 
high on the favorable tolerogenic list with the lung and 
intestine following and the kidney and heart bringing up the 
rear. Experimental studies showing less striking 
tolerogenicity of the lymphoreticular-rich spleen (77-79), 
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intestine (80), and lung (81,82) are compatible with this 
generalization. 
Sites of Alloactivation and Tolerization 
with Particular Reference to Leukocyte-Poor Organs 
By the end of 1992, it was concluded that all whole 
organs underwent the same process of potential tolerance 
induction as the liver, although the dynamics were not so 
easy to study except with the leukocyte-rich intestine 
(80,83-85) . However, the same kind of traffic in the 
context of alloactivation and rejection rather than 
tolerization, had been well worked out earlier with the so-
called lymphoid-poor organs including the kidney. Studies 
in untreated animals have shown that the alloreaction starts 
in 2 general sites, peripherally in the graft and centrally 
in the recipient lymphoid tissues. 
Central Alloactivation --- In a very complete study in 
1981 of untreated rat kidney recipients, Hayry and Nemlander 
and their associates (86) demonstrated extensive leukocyte 
migration to the spleen and elsewhere. If Hayry had given 
one or two doses of cyclosporine in his kidney 
transplantation experiments (which were with an "easy" 
strain combination) and had followed his animals further, he 
almost certainly would have uncovered the events of cell 
migration and long term repopulation that awaited another 
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dozen years for exposure with the liver (58). Larsen et al 
(87) found that donor dendritic cells from heterotopic 
cardiac allografts were released into the circulation, where 
they eventually homed into the T-cell areas of the recipient 
spleen. In the spleen, the donor cells initiate 
proliferation of recipient cells, and vice versa (86-90). 
This reaction might be thought of as an in vivo mixed 
lymphocyte response (MLR) and epitomizes central 
allosensitization with potential tolerization. 
Intragraft Alloactivation --- Allosensitization (and 
tolerization) presumably also occurs within the graft. 
Forbes et al (89) showed that clustering of recipient 
lymphocytes occurs around donor dendritic cells in the 
interstitium of cardiac grafts, within a few days after 
transplantation. The recipient lymphoid cells were 
undergoing blastogenesis and proliferation in these 
clusters. We have described analogous events in rejecting 
rat livers (88). 
In human recipients of kidney grafts (91,92) under 
cyclosporine-prednisone immunosuppression, Hayry and 
Willebrand noted what appeared to be a bidirectional MLR in 
needle aspiration biopsies. When studied with the 
Staphylococcus au reus assay and alloantibodies to non-shared 
donor and recipient allelic specificities, most of the 
collected blast cells in some cases were derived from the 
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donor or else the response was split, "resembling a 
bidirectional mixed lymphocyte reaction in vitro" (91) 
In these models, the difference from the experiments 
with liver transplantation appear to be quantitative. With 
the smaller number of passenger leukocytes, there is a 
greater tendency to allosensitization and less to 
tolerogenicity. Nevertheless, Corry (93) and Russell et al 
(94) showed that tolerance without drug induction could be 
induced by heart and kidney transplantation between weakly 
MHC incompatible strains of mouse recipients. 
The Parking Experiments --- Earlier evidence that the 
disseminated passenger leukocytes play a crucial role in 
allograft rejection came from elegant studies by Lechler and 
Batchelor (75,76), who demonstrated that rat allogeneic 
kidneys were indefinitely accepted if they were first 
"parked" in the immunosuppressed recipient and subsequently 
re-transplanted secondarily into naive animals syngeneic to 
the recipient strain (75,76). However, these kidneys were 
acutely rejected if the animals receiving the re-transplants 
were intravenously injected with donor strain dendritic 
cells (76). This was the first direct evidence that the 
immunogenecity of a passenger cell depleted allograft and 
could be restored by addition of donor strain dendritic 
cells. Similar observations were also made by Benson et aI, 
(95) who showed that deoxyguanosine treated fetal thymus 
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allografts were rejected if transplanted into animals primed 
with donor-strain dendritic cells. 
Unfortunately, results with the experimentally useful 
parking model have been extrapolated overly freely to 
discussions and criticisms of the cell migration and 
microchimerism concepts. In the parking experiment, neither 
the host immunocytes (including those that home to the 
parked organ) nor the donor leukocytes seeded ubiquitously 
in the recipient remain the same. The changes have been 
shown dramatically in rat liver transplant experiments in 
which the "passenger leukocyte" load brought in with the 
liver was augmented by donor bone marrow simultaneously or 
at an earlier time. Staged delivery of the donor leukocytes 
caused fulminant GVHD. Aside from clarifying limitations in 
interpretation of parking experiments, these studies have 
significant clinical implications in planning the staged use 
of bone marrow for the augmentation of passenger leukocytes 
(58) . 
The Fate of Passenger Leukocytes in Treated Recipients 
Immunosuppressive drugs such as FK 506 do not grossly 
alter the migration of donor hematolymphoid cells out of an 
allograft (58,96,97). However, almost all 
immunosuppressants markedly reduce the infiltration of 
recipient cells into the graft. They also protect the graft 
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from injury and prolong the survival of donor passenger 
leukocytes, both within the graft and peripherally in the 
recipient tissues (58,96,97). Additionally, neither FK 506 
nor cyclosporine abolish the immune response in recipient's 
lymphoid tissues provoked by the passenger leukocytes 
(58,98,99) . They merely diminish it, and possibly alter the 
response in a qualitative fashion (58,98,99). 
Over time, the peripheralized donor cells can be 
identified in the recipient's skin, visceral organs and 
lymphoid tissues, including the bone marrow and thymus 
(58, 97) . This ubiquitous distribution argues against 
passive spread via draining lymphatics. Moreover, homing of 
the donor cells to the same anatomic locations as their 
phenotypically identical counterparts argues for the 
existence of preprogrammed migratory routes, which are 
independent of allogeneic barriers (99-102). Thus, 
immunosuppressive drugs regardless of their molecular site 
of action, appear to have a permissive and regulatory, 
rather than a purely inhibitory effect on the interactions 
between donor and recipient hematolymphoid cells {56, 58). 
Even under the protection of continuous 
immunosuppression, the number of donor cells that have 
emigrated out of transplanted organs gradually decreases 
with time {58, 59). One likely explanation for this finding 
is that the majority of the transferred donor cells have a 
341 
mature phenotype, and therefore are eventually eliminated by 
the recipient's immune system. Or if they are terminally 
differentiated and are incapable of further division, they 
simply die out. Finally, it is possible that a few donor 
progenitor cells "engraft" and produce a very small number 
of peripheralized donor cells, which can persist for many 
years in the tissues of stable organ allograft recipients. 
To designate this condition, we have used the term 
"micro-chimerism" that was originally coined by Liegeois et 
al (30,31) and popularized by Monaco (34). If, however, 
"microchimerism" is of importance in tolerance, any 
hypothesis explaining the mechanisms must account for an 
effect of the donor cells, which far exceeds their number 
(52-59) . 
Macro- versus Microchimerism 
Because these 2 terms have been used in different ways, 
it is important for this discussion to define our meaning. 
It is generally accepted that stable hematolymphoid 
macrochimerism is synonymous with allogeneic tolerance. 
Radiation models, such as those described by Ildstad and 
Sachs (17) and the human fetal-liver recipients described by 
Touraine (103), have defined mixed hematopoietic 
macrochimerism using flow cytometric studies. This 
technology can confidently discriminate between allogeneic 
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populations when one component is as small as 1.0%. 
Although, individual contributions to the total pool 
reciprocally may vary between 10 and 90 percent, 
hematopoietic cell lineages from both donor and recipient 
can usually be detected. 
In vitro immunologic testing in the mouse models of 
macrochimerism reveals a donor specific proliferative defect 
and lack of donor-directed cytolytic activity, while the 
same responses to third party lymphocytes remain intact 
(17) . This in vitro state of nonreactivity may not be 
absolute in higher species. For example, the human 
macrochimeras reported by Touraine and Roncarolo et al (103) 
show host reactive cells in vitro. Yet, such patients have 
no obvious GVHD and the donor cells appear to be under a 
regulatory influence, perhaps mediated by cytokines or other 
cells. 
In a different context, Thomas et al have used the word 
microchimerism to describe nodules of donor leukocytes found 
on the capsule of renal allografts in subhuman primates 
rendered donor specific tolerant by adjuvant bone marrow 
infusion and ALG plus total lymphoid irradiation (104). 
"Microchimerism" as reported by us in humans (52-57) 
and in animals (58,59) refers to the diffuse rather than 
localized presence in recipient tissues of donor cells at 
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levels below the detection threshold of flow cytometry, thus 
requiring alternative methods of identification (52-59) 
Donor cell labeling using immunocytochemistry with anti-MHC 
monoclonal antibodies or in situ hybridization for 
mismatched sex chromosomes can detect donor cells present in 
recipient tissues in concentrations between 1:1000 and 
1:5000. Polymerase chain reaction studies for mismatched 
HLA-DR alleles or the Y chromosome is even more sensitive. 
As few as one cell in 40,000 can be identified. 
Because of the paucity of cells present in 
microchimerics, it is difficult to define multiple lineages 
in a single stable patient. However, mUltilineage chimerism 
has been shown in several humans (105-107) after liver 
transplantation. In rat and mouse studies (58,59), 
different lineages are found as long as 300 days after 
transplantation. 
In vitro immunologic testing of "microchimeras" may 
show donor specific hyporeactivity, but intact MLR and CML 
responses may also be seen (49,59,104,108,109). This is not 
surprising, since Strelein et al (110) has shown before in 
neonatal chimeras, that in vitro immunologic testing may not 
always reflect, or predict, in vivo tolerance. No matter 
what the outcome of in vitro assays, recipients often 
tolerate allografts in vivo in the same way as the 
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macrochimeric recipients cited above 
(49,59,104,108,109,111) . 
The Commonality of Treatment Regimens 
to Induce Chimerism and Tolerance in Adults 
Regimens used to induce allogeneic tolerance in the 
adult animal (or in humans) have in common two factors, 
donor allo-antigen, which is a specific requirement, and 
non-specific immunosuppression for variable periods (13-19) 
With the possible exception of the liver (59), donor bone 
marrow has been the best source of "tolerogenic 
alloantigen". The best choice of immunosuppression remains 
controversial, but virtually all potent modalities achieve 
the same end result in spite of their widely variable 
mechanisms. For example, cytotoxic drugs that inhibit DNA 
synthesis, cyclosporine, FK 506, monoclonal antibodies, 
radiation, cytokine therapy, or nothing at all except donor 
tissue have all been used to induce tolerance with variable 
success (13-19,52-59). 
A very important concept that emerges in the 
development of all of these regimens is that too much 
immunosuppression can block the induction of tolerance 
(112), implying that it is an active process. Wood et al 
(112) and Liegeois et al (30,31) have particularly 
emphasized this point as well as the dynamic nature of 
tolerance. It is also known that the dose and timing of 
alloantigen presentation influences the final outcome of 
tolerance induction (13-19,30,31,52-59). These 
considerations are not different from those required to 
induce tolerance to self or other non-allogeneic antigens 
(106,113,114) . 
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Because of the passenger leukocyte migration and 
repopulation that now are known to be a generic phenomena 
after the engraftment of all whole organs, every such 
clinical operation has the theoretic potential for 
initiating tolerance induction. However, this does not 
happen reliably, and despite the co-existence of both 
alloantigen and immunosuppression, drug-free graft 
acceptance is an uncommon clinical outcome. Nevertheless, 
the ability to eventually withdraw immunosuppressive drugs 
without initiating graft rejection has often been documented 
in clinical reports, particularly after liver 
transplantation (57,115), and can be routinely accomplished 
in numerous experimental transplantation models (58,59). 
Drug withdrawal is least often achieved without 
complications in kidney and heart allograft recipients (57). 
One obvious difference between these organs is the 
number of passenger leukocytes, which is higher in the bone 
marrow and liver than in heart or kidney. However, in the 
ensuing paragraphs, we will first globally and then 
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specifically attempt to describe how the presence of donor 
leukocytes, even in small numbers, can promote allograft 
acceptance. Our hypothesis is based on a network viewpoint 
of the immune system (116-123). 
Global Hypothesis 
Transplantation of a solid organ without the need for 
continual immunosuppression requires in some respect, 
redefinition of the recipient's immunologic self (116) Co-
transplantation of a fragment of the donor's immune system 
(i.e., passenger leukocytes of solid organ grafts, or bone 
marrow augmentation), whose normal function is to define the 
donor's immunologic self, would appear to be most capable of 
achieving this task (116-117). In fact, the desire to induce 
hematolymphoid chimerism for promoting allograft acceptance 
is knowingly or unknowingly, based on this idea and in 
essence, is an attempt to merge two different immune 
systems. 
This merger however is resisted by mature cells in both 
immune networks, which mediate classical alloimmune 
reactions and NK cells, which can prevent allogeneic 
progenitor cell engraftment (124,125). Any maneuver that 
results in the combination of less immunogenic and more 
plastic donor and recipient hematolymphoid progenitor cell 
populations lessens the resistance. Therefore, most 
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investigators have used depletion of mature cells from the 
donor inoculum and ablation of donor reactivity in the 
recipient by cytoreductive or radiation therapy (13-19). It 
is now realized that transplant surgeons have been 
unknowingly protecting the passenger leukocyte (donor immune 
system) by various forms of immunosuppression while it 
carried out immunologic redefinition of the recipient (52-
57) . 
The concept of MHC restriction however, appears to 
limit the interactions that could occur between allogeneic 
lymphoid cells to antagonistic ones. But, if these 
engagements are viewed as receptor-ligand interactions of 
varying "fits" or affinities, the possibility of cooperative 
interactions occurring between allogeneic cells is not 
unreasonable (116-123). In fact, effective collaboration 
between allogeneic APC's and lymphocytes within a single 
chimeric immune network has been shown before in a chimeric 
human (103). "Cross-talk" between the allogeneic cells of 
both populations comprising a fully integrated chimeric 
immune system is the ultimate goal. 
The key component for establishing and maintaining 
tolerance in a chimeric allogeneic network would be donor 
cells or antigen if immunologic self definition is 
maintained by self assertion as Coutinho suggests (116). 
This requirement for the presence of the tolerated antigen 
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is not different from that of classical explanations of 
allogeneic tolerance (114,126-128). The major difference 
between these two views turns on whether tolerance is an 
active or passive process. Under either circumstance, the 
donor cells provide the necessary signals to imprint 
specificity and inhibit the development of effector 
responses (112,114,126). 
From this viewpoint, it becomes very difficult to 
dispute that hematopoietic chimerism is essential for 
successful organ engraftment, whether this is at a macro or 
micro level. The direct relation of acquired tolerance (and 
GVHD) with chimerism discovered by Billingham, Brent and 
Medawar (12,23) was formally verified by Russell (129) who 
reversed both tolerance and --- runt disease (GVHD) with the 
elimination of the chimerism with antidonor leukocyte 
antibodies. The only debate is the quantity of donor 
leukocytes required. This may be a moot point if the 
iterative and metadynamic properties of an immune network 
are considered (116-123). The mobile donor hematolymphoid 
cells released from the graft during the first week or so 
after transplantation provoke an initial burst of 
alloreactivity in the recipient's lymphoid tissue. Under 
the protection of immunosuppression they also begin to 
participate alongside recipient cells in preprogrammed 
migratory routes (e.g. through the thymus and lymphoid 
tissues) (58,97). Exposure of immature recipient cells to 
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donor dendritic and other leukocyte populations during 
thymic or early post-thymic maturation gradually erodes the 
basis for alloreactivity and the singular identity of the 
recipient's "immunologic self". 
The education or re-education process is made easier if 
the merging populations consist of relatively immature and 
more malleable uncommitted progenitor cells, like those seen 
in neonates. Such cells have more ready access to 
"immunologic privileged" sites such as the thymus and spleen 
and serve as a renewable source of cells. However, 
regardless of their age, mixing of allogeneic hematolymphoid 
populations would eventually exert selection pressures on 
various receptor specificities, such that evolution of the 
chimeric mixture would occur. Genetic restriction of 
receptor configurations may ultimately determine whether a 
dynamic equilibrium is ever reached (116-123). 
MECHANISTIC HYPOTHESIS 
A network-based viewpoint categorizes immune responses 
as receptor-ligand interactions, occurring between the 
receptors on various participating cellular populations 
(116-123). For example, CD4+ T cells are originally 
selected in the thymus on the basis of their affinity for 
self-MHC class II antigens, that are expressed on the 
surface of antigen presenting cells (APC) (130,131). Cells 
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with an extremely high or low affinity or "fit" for self MHC 
class II are negatively selected and therefore not 
represented in the peripheral T cell pool. Cells with 
receptors of intermediate affinity are positively selected 
on the basis of limited "autoreactivity (anti-self class 
II)", and released from the thymus to participate in immune 
responses. 
In the periphery, alterations of self-MHC class lIon 
an APC, induced by binding of an exogenous peptide, changes 
the affinity of these cells for receptors on CD4+ T cells, 
which in turn results in T cell activation (132-134). The 
activated CD4+ T cells then develop idiotypes that are 
antigenic to a subgroup of anti-idiotypic regulatory T 
cells. The regulatory cells are thought to recognize the 
class II MHC/T-cell receptor complex present on the 
activated CD4+ T cells (anti-anti-self) (Figure 1) and 
thereby prevent uncontrolled autoreactivity. The anti-anti 
self MHC class II/receptor on the regulatory T-cells 
resemble the self-MHC class II antigens present on the 
original stimulatory APC's, and because of this have been 
called "MHC-image" (MHCi) cells (119,120). Such cells have 
been identified during and after exposure to toxins, nominal 
antigens and graft- versus-host and allogeneic reactions 
(135-142). We would suggest however, that antibodies also 
could provide an MHCi, and function with the regulatory MHCi 
cells in a "suppressor-like" fashion, showing high network 
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Figure 1. Diagrammatic presentation of the theory of "Network Focusing". 
CD4+ T cells 
Self APC 
Donor/Self MHCi 
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connectivity (i.e few cells would regulate many others) 
(116-123) . The entire concept is illustrated in Figure 1 
has been referred to as "network focusing" (119,120). 
We propose that an alloreaction is not fundamentally 
different from other immune responses. It is subject to 
similar regulatory controls. In fact, the essence of our 
hypothesis is that the alloreaction itself gives birth to 
the tolerogenic cells by imprinting on the recipient's 
immune network an internal image of the donor. Furthermore, 
allogeneic tolerance is maintained by specific autoimmune 
reactions, which are fueled by the presence of donor 
hematolymphoid cells (Figure 2). Over time the continued 
participation of donor cells in the recipient's immune 
network gradually erodes the previously strong barriers that 
prevent effective cooperation between allogeneic networks 
(58,143) The following paragraphs describe how this could 
occur. 
spontaneously alloreactive T cells comprise about 1% of 
the total peripheral T cell pool, and have been shown to 
crossreact with self-APC bearing a nominal antigen (132-
134). Because of this crossreactivity, an immune network 
would likely be unable to reliably distinguish between an 
alloreaction and response to other antigens (132-134). 
However in an alloresponse, the MHCi cells are selectively 
stimulated on the basis of receptor complementarity to 
353 
Graft Destruction 
a) ~ 0 Allograft ..... (.) 
~ t <.;...; (il 
C 
Sensitized Recipient 
0 
..... 
ell 
~ 
(1) 
~ 
b) ~ 0 kfl~ ..... (.) ~ <.;...; 
(il 
c ~ 0 ..... ell "3 'a{J (1) 
Naive Recipient 
c:::: 
c) 
~ 
0 
..... 
(.) 
~ <.;...; 
(il 
c 
Enhanced Recipient 
0 
..... 
ro 
"3 
'a{J 
~ 
c:::: 
TIME 
Figure 2. Schematic representation of an alloresponse of a sensitized (a); naive 
(b); and enhanced (c) reCipients. Time post-transplant is represented on the x-
axis. The positive displacement on the Y-axis symbolizes the strength of the 
effector phase [Le. rejection reaction]. The negative quadrant on the Y-axis 
represents the regulatory responses. which at present are poorly understood. 
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alloreactive CD4+ T cells (anti, anti-donor MHC). Suciu-
Foca et al (136,137) have provided direct evidence that such 
cells do indeed exist. They have shown that alloactivated T 
cells develop idiotypic-like determinants, which elicit an 
autologous mixed lymphocyte response. This active response 
was shown to exhibit both specificity and memory in the 
primed lymphocyte test, which failed to exhibit secondary 
reactivity to autologous blasts primed against a different 
allospecificity (136,137). Thus, the early brisk 
alloreaction provoked by the initial influx of donor cells 
into recipient lymphoid tissues, would begin to create an 
internal image of the donor in the recipient's immune system 
(58,98,99) . 
The initial alloreaction also generates effector 
mechanisms, which have the potential to damage both the 
graft and mobile cells. If however, the graft and the 
migratory cells survive the effector response, the 
regulatory reaction described above, which is 180 degrees 
out of phase with the effector response (Figure 2), will 
eventually self-limit the rejection. Continual 
restimulation of the alloreaction, as would be seen with the 
survival of microchimeric hematolymphoid cells, would in 
turn also recruit the regulatory cells carrying the donor-
MHCi. Thus, alloreactive and auto-alloreactive MHCi 
regulatory reactions would be in a constant flux, resulting 
in a dynamic and at times unstable equilibrium (116). 
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Meanwhile, the continued trafficking and participation of 
donor hematolymphoid cells in the recipient's immune system 
eventually would result in further erosion of the basis for 
alloreactivity (58,143). 
The explanation of donor specificity of allogeneic 
tolerance is obvious from our hypothesis. It is also clear 
how too much immunosuppression could prevent tolerance 
induction. Specificity is conferred by the presence of 
donor cells, or antigen maintaining the donor MHCi. Overly 
aggressive immunosuppression would not only inhibit the 
regulatory reactions, but also prevent donor cell division, 
which is particularly important during the formative stages 
of tolerance induction. Elegant studies by Russell et al 
(144,145) illustrate these points. 
They attempted to provoke destruction of an accepted 
kidney allograft in a "tolerant" recipient by infusion of 
syngeneic lymphoid cells, which had already been sensitized 
to the donor. Although they succeeded in causing graft 
rejection, it was only transient. The graft recovered and 
the recipient returned to a tolerant state (144,145). 
Complete immunologic graft destruction required treatment 
with donor leukocytes (antigen) I combined with 
cyclophosphamide pretreatment and/or continual BCG 
immunostimulation after delivery of the donor cells. These 
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manipulations would either prevent or overwhelm respectively 
the regulatory responses. 
Actively enhanced recipients, when subsequently 
challenged with an allograft, initially experience rejection 
that spontaneously resolves (146). This includes marked 
upregulation of donor MHC antigens (146), which has led 
several authors to conclude that the pretransplant blood 
transfusions are powerfully immunosuppressive. The active 
components in transfusions are known to be class II-bearing 
donor hematolymphoid cells (147-151). It is proposed that 
this form of pre-transplant conditioning (active 
enhancement) bolsters the regulatory reactions, outlined 
above and represent a "vaccination" or an indirect 
stimulation of donor MHCi cells. When the enhanced subject 
is subsequently challenged with an allograft, rejection is 
internally controlled before it is able to destroy the graft 
(Figure 2) . 
Wotherspoon et al (152) have provided more direct 
evidence that the alloreactive cell are capable of tolerance 
induction. They showed that cells capable of transferring 
allogeneic tolerance (or resistance to GVHD) also bear 
receptors for the tolerated alloantigen. Strelein et al 
(153) have summarized a similar experience in neonatal 
chimeras by showing the importance of "tolerogen-specific T 
cells" in the maintenance of tolerance. Qin et al (154) 
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provided evidence that tolerance could be transferred with T 
cells across as many as four generation, a phenomenon he 
called "infectious" tolerance. We believe that idiotypic 
determinants on T-cells provide a rational explanation for 
the above observations, and are similar to the reasoning 
behind using effector cell vaccination for preventing 
autoimmune allergic encephalitis (155). 
The association and importance of "autoimmune 
reactions" in the establishment and maintenance of 
allogeneic tolerance has been particularly well studied in 
neonatal chimeric mice (153,156-161). Briefly, chimeric 
donor B and possibly other cells are thought to constantly 
stimulate recipient CD4+ cells, that show a TH2-type 
profile. These tolerogen-specific, TH2-type alloreactive 
CD4+ cells are unable to coordinate an effective rejection 
reaction, and in fact, inhibit the response through the 
secretion of IL-4 and possibly other TH2-type cytokines 
(153,159,160). The elevated IL-4 also results in 
upregulation of class II MHC on the chimeric donor B-cells, 
B-cell hype=activity and secretion of autoantibodies 
directed at DNA, smooth muscle cells and basement membrane 
constituents (153,156-161). 
Autoimmune reactions triggered by heavy metal 
injections or transient cyclosporine therapy share many 
features of the autoimmunity observed in the chronic GVHD 
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models (162-166) described above. The BN rat is 
particularly sensitive to both of these syndromes, which 
appear to be dependent on autoreactive anti-Ia CD4+ T cells 
(162-165). Zhang et al (166) have shown that these auto-
reactive T cells are capable of prolonging heart allograft 
survival, and we have recently shown that BN recipients of 
LEW liver allografts also retain hematolymphoid chimerism 
for more than 300 days after liver transplantation, even 
without continual immunosuppressive therapy (58). More 
interestingly, BN recipients of LEW intestinal or liver 
allografts experience a lethal graft versus host disease, 
even when the percentage of donor cells is <5% of the total 
lymphoid cell population (167). We currently are testing 
the hypothesis that although LEW donor cells are fewer in 
number, they receive assistance from "autoimmune" reactions 
precipitated by the alloreaction in the recipient's immune 
network. 
The above hypothesis is similar to the hypotheses of 
van Rood et al (151) and Dorsch and Roser (168,169), 
although, there are key differences as well. Both of the 
groups just mentioned, stress the need for hematolymphoid 
chimerism and anti-idiotypic-like reactions. However, they 
also stress the necessity of MHC restriction and view the 
relationship between the two immune systems as one of 
antagonism. In contrast, we stress the possibility of 
effective collaboration across MHC barriers with "auto-
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reactivity" ultimately being responsible for graft 
acceptance. Furthermore, we feel that the "autoimmune"-type 
reactions described in the preceding pages are likely part 
of the repertoire of a normally functioning immune network 
(116-123) . 
It should be mentioned that Shearer et al (170) and 
Hoffman et al (171) have used the concept of network 
focusing to explain the pan-immunologic deficit of the 
Acquired Immune Deficiency Syndrome (AIDS). They suggested 
that the combination of allogeneic lymphoid cells and HIV 
trigger chronic GVH and autoimmune reactions, which are 
internally directed against the CD4+ components of the 
immune network. The end result is overactivity of the MHCi 
system, which produces an immune defect that is far greater 
than would be expected if the virus alone were causing the 
disease. 
From the preceding discussion, it would appear that 
specific allogeneic tolerance is something easily and 
reproducibly achieved. Such is not the case in clinical 
organ transplantation and therefore immunosuppressive 
protocols tend to be designed to completely abolish all 
alloreactivity. Our hypothesis would suggest that such an 
approach is not conducive to tolerance induction and 
eventual drug withdrawal. We now know that there are many 
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more considerations to the induction of tolerance besides 
the elimination of rejection. 
In fact, without alloactivation, there will be no 
tolerance. Effective immunosuppressants appear to function 
at least in part by permitting regulatory responses to 
occur, while protecting both the peripheralized donor 
hematolymphoid cells and graft from injury {52-58,98,99} 
All the while, donor cells are assimilated into the 
recipient's immune network. In addition, FK 506 and 
cyclosporine change thymic physiology, by increasing the 
emigration into peripheral tissue of immature thymocytes 
{172,173}, and increasing the recruitment into the thymus of 
immature medullary dendritic cells {174}. 
The type of allograft may also play an important role 
in the induction of transplantation tolerance. For example, 
the liver contains a large number of natural killer cells, 
which can assist in donor hematolymphoid cell engraftment 
(175). The liver also is known to be intimately involved 
with regulation of hematopoietic stem cell activity in the 
bone marrow {176,177}. All of the considerations in the 
preceding two paragraphs could potentially influence the 
merging of two immune systems. 
At present however, we do not know how to measure or 
control potentially beneficial regulatory responses. More 
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importantly, we also do not know which factors dictate 
whether an alloantigen exposure will result in sensitization 
or tolerance. These two seemingly opposite reactions are 
obviously quite closely related. Nevertheless, empiric 
observations have shown that increasing the donor's immune 
system representation is advantageous for tolerance 
induction. Therefore, non-cytotoxic regimens are needed to 
enhance the survival or permit engraftment of donor 
hematolymphoid cells to accomplish immunologic redefinition 
of the recipient. Regardless of the specific approach, 
increasing attention to the network properties of immune 
systems will likely be required. 
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